MY119030A - Purified immunoglobulin - Google Patents

Purified immunoglobulin

Info

Publication number
MY119030A
MY119030A MYPI91001909A MYPI9101909A MY119030A MY 119030 A MY119030 A MY 119030A MY PI91001909 A MYPI91001909 A MY PI91001909A MY PI9101909 A MYPI9101909 A MY PI9101909A MY 119030 A MY119030 A MY 119030A
Authority
MY
Malaysia
Prior art keywords
reducing conditions
exhibits
preparation
major peaks
reduced sample
Prior art date
Application number
MYPI91001909A
Other languages
English (en)
Inventor
Paul Ian Nicholas Ramage
Geoffrey Allen
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10683866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY119030(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of MY119030A publication Critical patent/MY119030A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI91001909A 1990-10-17 1991-10-16 Purified immunoglobulin MY119030A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909022547A GB9022547D0 (en) 1990-10-17 1990-10-17 Purified immunoglobulin

Publications (1)

Publication Number Publication Date
MY119030A true MY119030A (en) 2005-03-31

Family

ID=10683866

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI91001909A MY119030A (en) 1990-10-17 1991-10-16 Purified immunoglobulin
MYPI92001385A MY136210A (en) 1990-10-17 1991-10-16 Purified immunoglobulin

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI92001385A MY136210A (en) 1990-10-17 1991-10-16 Purified immunoglobulin

Country Status (29)

Country Link
US (1) US5644036A (cg-RX-API-DMAC7.html)
EP (1) EP0504363B2 (cg-RX-API-DMAC7.html)
JP (1) JP2638680B2 (cg-RX-API-DMAC7.html)
KR (2) KR960015399B1 (cg-RX-API-DMAC7.html)
AT (2) ATE162552T1 (cg-RX-API-DMAC7.html)
AU (3) AU658926B2 (cg-RX-API-DMAC7.html)
BE (1) BE1004226A5 (cg-RX-API-DMAC7.html)
BR (1) BR1100358A (cg-RX-API-DMAC7.html)
CA (1) CA2069481C (cg-RX-API-DMAC7.html)
CH (2) CH681455A5 (cg-RX-API-DMAC7.html)
DE (1) DE69128774T3 (cg-RX-API-DMAC7.html)
DK (1) DK0504363T4 (cg-RX-API-DMAC7.html)
ES (2) ES2112865T5 (cg-RX-API-DMAC7.html)
FI (2) FI110003B (cg-RX-API-DMAC7.html)
FR (2) FR2668164A1 (cg-RX-API-DMAC7.html)
GB (2) GB9022547D0 (cg-RX-API-DMAC7.html)
GR (3) GR910100425A (cg-RX-API-DMAC7.html)
HU (1) HUT64601A (cg-RX-API-DMAC7.html)
IE (1) IE913560A1 (cg-RX-API-DMAC7.html)
IL (3) IL102726A (cg-RX-API-DMAC7.html)
IT (1) IT1250064B (cg-RX-API-DMAC7.html)
LU (1) LU88122A1 (cg-RX-API-DMAC7.html)
MX (1) MX9203794A (cg-RX-API-DMAC7.html)
MY (2) MY119030A (cg-RX-API-DMAC7.html)
NZ (2) NZ244114A (cg-RX-API-DMAC7.html)
PT (2) PT99248B (cg-RX-API-DMAC7.html)
TW (1) TW283710B (cg-RX-API-DMAC7.html)
WO (1) WO1992007084A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA918259B (cg-RX-API-DMAC7.html)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
IL103418A (en) * 1991-10-15 1997-11-20 Wellcome Found Therapeutic agent for the t-cell mediated inflammation of the joints and its production
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB9300501D0 (en) * 1993-01-09 1993-03-03 Wellcome Found Purification of immunoglobulin
NZ315357A (en) † 1995-08-01 1999-08-30 Pasteur Merieux Serums Vacc Method for industrially producing a japanese encephalitis vaccine, and resulting vaccine
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
WO1997029131A1 (en) * 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
EP2336149A1 (en) 2001-03-09 2011-06-22 Chugai Seiyaku Kabushiki Kaisha Protein purification method
JP4288153B2 (ja) * 2001-06-05 2009-07-01 ジェネティクス インスティテュート，エルエルシー 非常に陰イオン性であるタンパク質を精製する方法
GB0220894D0 (en) * 2002-09-09 2002-10-16 Millipore Uk Ltd Method of separation
EP1561756B1 (en) 2002-09-11 2015-12-23 Chugai Seiyaku Kabushiki Kaisha Method of purifying protein
EP2314604A3 (en) 2002-10-15 2011-05-25 Intercell AG Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
BRPI0417993A (pt) * 2003-12-22 2007-04-27 Genzyme Corp anticorpo anti-cd52 para tratamento da diabetes
CN104610422A (zh) * 2005-03-11 2015-05-13 惠氏公司 弱分配层析的方法
KR101463631B1 (ko) 2006-03-31 2014-11-19 추가이 세이야쿠 가부시키가이샤 항체의 혈중 동태를 제어하는 방법
RU2510400C9 (ru) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
US20110111406A1 (en) 2008-04-11 2011-05-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
AU2010248935B2 (en) 2009-05-13 2016-12-15 Genzyme Corporation Methods and compositions for treating lupus
SG176060A1 (en) 2009-05-13 2011-12-29 Genzyme Corp Anti-human cd52 immunoglobulins
WO2011090719A2 (en) * 2009-12-29 2011-07-28 Dr. Reddy's Laboratories Ltd. Protein purification by ion exchange
US20130096284A1 (en) 2010-06-21 2013-04-18 Kyowa Hakko Kirin Co., Ltd. Method for purifying protein using amino acid
RU2467783C2 (ru) * 2010-07-30 2012-11-27 Закрытое акционерное общество "БиоХимМак СТ" Способ хроматографического выделения иммуноглобулина
WO2012073992A1 (ja) 2010-11-30 2012-06-07 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
WO2014035475A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
BR112016014824A2 (pt) 2013-12-27 2017-09-19 Chugai Pharmaceutical Co Ltd Método para purificar anticorpo que tem ponto isoelétrico baixo
AR103161A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
EP3330279B1 (en) 2015-07-31 2022-04-06 Chugai Seiyaku Kabushiki Kaisha Method for purifying composition comprising antibodies with anionic polymer
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
CA3031028C (en) 2016-07-25 2024-02-13 Lu Wang Affinity chromatography wash buffer
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
US20220177518A1 (en) 2019-03-29 2022-06-09 Asahi Kasei Medical Co., Ltd. Method for purifying protein
EP3954725B1 (en) 2019-04-08 2024-03-06 Asahi Kasei Medical Co., Ltd. Polyamide medium for purifying protein-containing solution and method for producing polyamide medium
TW202104244A (zh) 2019-04-10 2021-02-01 日商中外製藥股份有限公司 Fc區域改變抗體的純化方法
JPWO2022260091A1 (cg-RX-API-DMAC7.html) 2021-06-10 2022-12-15

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118796A (en) * 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
DE68909441T2 (de) * 1988-02-12 1994-02-10 British Tech Group Modifizierte Antikörper.

Also Published As

Publication number Publication date
FR2668164B1 (cg-RX-API-DMAC7.html) 1995-04-14
GB9022547D0 (en) 1990-11-28
FI110002B (fi) 2002-11-15
ITRM910788A0 (it) 1991-10-16
ITRM910788A1 (it) 1993-04-16
KR960015399B1 (ko) 1996-11-13
KR100193314B1 (ko) 1999-06-15
NZ240247A (en) 1994-03-25
ES2081742A1 (es) 1996-03-01
MX9203794A (es) 1992-07-01
PT99248B (pt) 1999-04-30
CA2069481A1 (en) 1992-04-18
DE69128774T3 (de) 2007-08-16
FI922380L (fi) 1992-05-25
ZA918259B (en) 1993-04-16
DE69128774D1 (de) 1998-02-26
GB2253397A (en) 1992-09-09
BR1100358A (pt) 2000-03-28
TW283710B (cg-RX-API-DMAC7.html) 1996-08-21
KR920703108A (ko) 1992-12-17
GR920100471A (el) 1994-06-30
AU716402B2 (en) 2000-02-24
EP0504363A1 (en) 1992-09-23
EP0504363B1 (en) 1998-01-21
FI110003B (fi) 2002-11-15
GR910100425A (el) 1992-09-25
FI922380A0 (fi) 1992-05-25
HU9202000D0 (en) 1992-10-28
AU7024294A (en) 1995-01-05
ZA926191B (en) 1993-04-16
ES2112865T3 (es) 1998-04-16
NZ244114A (en) 1995-06-27
AU8729491A (en) 1992-05-20
EP0504363B2 (en) 2007-02-07
LU88122A1 (fr) 1993-03-15
FI922824A0 (fi) 1992-06-17
CH681455A5 (cg-RX-API-DMAC7.html) 1993-03-31
JPH05504579A (ja) 1993-07-15
BE1004226A5 (fr) 1992-10-13
IL102726A (en) 2002-08-14
ES2081742B1 (es) 1996-10-01
DK0504363T3 (da) 1998-09-21
MY136210A (en) 2008-08-29
DK0504363T4 (da) 2007-05-29
CA2069481C (en) 2003-07-29
AU649078B2 (en) 1994-05-12
IE913560A1 (en) 1992-04-22
AU4521897A (en) 1998-02-12
PT100988B (pt) 1999-08-31
US5644036A (en) 1997-07-01
ATE162552T1 (de) 1998-02-15
AU2532192A (en) 1993-02-11
PT100988A (pt) 1994-02-28
FI922824L (fi) 1992-06-17
JP2638680B2 (ja) 1997-08-06
ATA900791A (de) 1996-06-15
GB9209529D0 (en) 1992-07-01
HUT64601A (en) 1994-01-28
FR2677997A1 (fr) 1992-12-24
AU658926B2 (en) 1995-05-04
WO1992007084A1 (en) 1992-04-30
PT99248A (pt) 1993-06-30
IT1250064B (it) 1995-03-30
ES2112865T5 (es) 2007-09-16
GR3026588T3 (en) 1998-07-31
IL102726A0 (en) 1993-01-31
DE69128774T2 (de) 1998-06-04
IL99761A0 (en) 1992-08-18
CH681305A5 (cg-RX-API-DMAC7.html) 1993-02-26
FR2668164A1 (fr) 1992-04-24

Similar Documents

Publication Publication Date Title
MY119030A (en) Purified immunoglobulin
AU4453896A (en) Activation of t-cells by modified, antigenic immunoglobulins
GR3026526T3 (en) Use of antibody-containing preparations for immunosuppression.
AU2671795A (en) Process and intermediate products for preparing cardiodilatin fragments, and highly purified cardiodilatin fragments
AU5733199A (en) Method for chromatographically purifying insulins
AU7044694A (en) Use of saturated, ring-containing compounds as clearing solvents
AU2808592A (en) Improved method for synthesis of desferrioxamine b, analogs and homologs thereof
GR3021988T3 (en) Anti-viral compounds
ES2139267T3 (es) Procedimiento para eliminar impurezas olefinicas de 2h-heptafluoropropano (r 227).
AU2629792A (en) Process for the purification of streptolysin 0, intact streptolysin 0 obtained by this process and its use
IT1241194B (it) Molla per cerniera di alette parasole per automobili.
MX9302629A (es) Purificacion del inhibidor-activador de plasminogeno 2 por cromatografia de inmunoafinidad.
IT1247534B (it) Anticorpo nl07 e relativo procedimento di produzione
IT1157502B (it) Antenna televisiva premontata, di ingombro riducibile e di rapido adattamento all'impiego
IT8206908V0 (it) Antenna televisiva premontata, di ingombro riducibile e di rapido adattamento all'impiego.
ITTV920068A0 (it) Struttura di dispositivo di serraggio, particolarmente per cinturini di orologi
TW368505B (en) A process for preparing cardiodilatin fragments; highly purified cardiodilatin fragments and intermediate products for the preparation of same
GB9402047D0 (en) Size exclusion chromatography